MedTrace Logo

Topical ASC-J9 Cream for Acne

NCT01289574 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2014-08-01

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and efficacy of topical 0.1% and 0.025% ASC-J9 creams applied twice daily for facial acne compared to vehicle control.

Conditions

Interventions

DRUG

ASC-J9

Cream for twice daily topical application to the face

Sponsors & Collaborators

  • Orient Europharma Co., Ltd.

    collaborator INDUSTRY

  • AndroScience Corp

    lead INDUSTRY

Principal Investigators

  • Jonathan S Dosik, MD · TKL Research

  • Chieh-Chen Huang, MD · Shih Kong Wu Ho-Su Memorial Hospital

  • Chih-Hsun Yang, MD · Chang Gung Memorial Hospital

  • Ting-Jui Chen, MD · Wan Fang Hospital

  • Wei-Ming Wang, MD PhD · Tri-Service General Hospital

  • Kuo-Hsien Wang, MD · Taipei Medical University Hospital

  • Ji-Chen Ho, MD · Chang Gung Memorial Hospital Kaohsiung Branch

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-07-31
Completion
2012-08-31

Countries

  • United States
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01289574 on ClinicalTrials.gov